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Surgical excision has traditionally been the treatment of choice for benign non-thyroid cystic 
neck masses, including lymphatic malformation, ranula, branchial cleft cyst, thyroglossal duct 
cyst, and parathyroid cyst. However, there is a tendency toward recurrence after surgery, and 
surgery may be accompanied by complications, including nerve injuries, vascular injuries, and 
scar formation. Ultrasound-guided sclerotherapy using various agents has been challenged and 
successfully applied as an alternative treatment for benign non-thyroid cystic neck masses. This 
report reviews the available sclerosing agents and describes the applications of sclerotherapy to 
the treatment of benign cystic masses in the neck. 
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Introduction
For the benign non-thyroid cystic neck masses, including lymphatic malformation, ranula, branchial 
cleft cyst, thyroglossal duct cyst, parathyroid cyst, and lymphocele, surgery is the first line of treatment. 
However, complete surgical removal may be difficult, resulting in a tendency toward recurrence, and 
the potential complications of surgery include muscle weakness, nerve damage, vessel damage, 
infection, and poor cosmetic outcomes such as scarring and stitch granuloma [1,2]. Although 
ultrasound-guided sclerotherapy for a benign thyroid cyst has been well established, ultrasound-
guided sclerotherapy for various non-thyroid cysts has been challenging but has become an accepted 
alternative treatment, and several authors have advocated sclerotherapy following surgery [2-5]. OK-
432 (picibanil) and ethanol are the most commonly used sclerosants among the variety of sclerosing 
agents that are currently available. This article reviews the most common uses of these agents and 
the indications and outcomes of sclerotherapy for benign cystic diseases of the neck. 
Sclerosing Agents
OK-432 and ethanol are the most widely used sclerosing agents, although numerous sclerosing 
agents have been used. When necessary, surgical excision after OK-432 treatment has not been 
considered more difficult. Ji-hoon Kim
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OK-432 (Picibanil)
OK-432 (Chugai Pharmaceutical, Tokyo, Japan) is a lyophilized 
mixture of a low-virulence strain (Su) of group-A Streptococcus 
pyogenes incubated with benzylpenicillin [1,3,6]. The agent was 
initially used for chemotherapy in patients with lung cancer or 
stomach cancer and to reduce malignant pleural effusions or 
ascites [6]. Since Ogita et al. [7] first reported the treatment of a 
lymphangioma via an intralesional injection of OK-432 in 1986, 
OK-432 sclerotherapy has been reported mainly for lymphatic 
malformations.
OK-432 sclerotherapy is usually performed using one vial (1 
Klinische Einheit; KE) of OK-432 mixed in 10 mL of normal saline, 
resulting in a 0.01-mg/mL dilution of OK-432 in a physiological 
solution [3,6]. If the volume of fluid aspirated from the cyst is <20 
mL, an equal quantity of the diluted OK-432 can be injected directly 
into the cyst cavity, and irrespective of the amount of fluid aspirated 
from the cyst, 20 mL is the maximum recommended volume of OK-
432. In the case of loculations, the total amount of diluted OK-432 
can be divided for injection into each cavity [3].
Although the mechanism of action of OK-432 sclerotherapy is 
not clearly understood, it is known that the collapse and adhesion 
of the cystic wall occur after the absorption of the injected OK-
432 solution. OK-432 causes inflammation of the cyst wall and 
stimulates the immunocyte secretion of a variety of cytokines, 
including interleukin-6, tumor-necrosis factor, and interferon 
gamma, which increases the permeability of the endothelium and 
induces the apoptosis of the lymphatic endothelium, facilitating the 
excretion of the lesion into the lymphatic vessels and resulting in a 
contraction of the cyst. The agent also promotes cyst contraction by 
activating natural killer cells and recruiting T-lymphocytes [1,3,8].
The skin test for penicillin G allergy should be performed before 
OK-432 sclerotherapy [8]. OK-432 sclerotherapy may initially be 
associated with minor inflammatory responses such as swelling, 
erythema, pain, and mild fever for up to 5 days in many cases, 
and it is rarely associated with major side effects such as dyspnea 
and cellulitis [6]. Kim et al. [1] have reported that 36 of 75 
patients experienced minor adverse effects including fever (n=14), 
odynophagia (n=12), local pain (n=19), and/or swelling (n=10) 
after the treatment of benign neck cysts with OK-432 sclerotherapy. 
The therapeutic response of OK-432 usually occurs about 6 weeks 
or more after treatment [6].
Ethanol
Ethanol is a less expensive and more potent sclerosing agent 
than OK-432. Its mechanisms of action include rapid dehydration 
of the cyst wall, protein denaturation that results in clumping of 
blood cells, and vessel wall necrosis that results in thrombosis and 
occlusion [9,10]. The potential side effects of ethanol sclerotherapy 
are known to be relatively more severe than those associated with 
OK-432. Serious complications have included nerve injury, skin 
necrosis, hemoglobinuria, and severe hypotension. There have 
been a few case reports of cardiopulmonary collapse, pulmonary 
hypertension, and death after alcohol embolization, which suggests 
that acute injection of ethanol may cause serious side effects on the 
pulmonary circulation [9,10].
Therefore, special care must be taken to avoid leakage during 
the injection of ethanol. Mason et al. [9] reported the safe dose of 
ethanol to be 1.0 mL/kg (body weight) to prevent complications, 
including respiratory depression, cardiac arrhythmias, seizures, 
rhabdomyolysis, and hypoglycemia. Further research aimed at 
enhancing the safety and efficacy of ethanol sclerotherapy is 
warranted [8,9,11]. 
Other Sclerosing Agents
Bleomycin is an antineoplastic agent that inhibits DNA synthesis 
and has sclerosing effects on lymphatic malformations. However, 
the use of bleomycin as a sclerosing agent is problematic because 
it can cause pulmonary fibrosis [6,12]. The tetracycline derivative 
doxycycline is also an effective sclerosant. However, doxycycline 
can cause severe discomfort or pain that typically lasts for 1 to 
3 hours after injection [6]. Many other agents, including boiling 
water, quinine, urethane, iodine tincture, nitromin, hypertonic saline, 
salicylates, cyclophosphamide, sodium morrhuate, sodium tetradecyl 
sulfate, fibrin glue, Ethibloc, and 50% dextrose have been used or 
tried for sclerotherapy [6,8]. Fibrin glue is expensive, and Ethibloc 
may cause an allergic reaction [8].
Indications for Sclerotherapy
With respect to efficacy, sclerotherapy has been found to have better 
results in the case of unilocular cysts than in the case of multilocular 
cysts and has proven more effective for lymphatic malformation 
than for ranula, branchial cleft cyst, or thyroglossal duct cyst [1,13]. 
Lymphatic Malformation
Lymphatic malformation is a congenital malformation of the 
lymphatic system that consists of cysts of various sizes. It is also 
called a lymphangioma or a cystic hygroma [6]. The management 
of lymphatic malformation is challenging. Although surgery is the 
mainstay of treatment, complete surgical excision may be difficult 
and is accompanied by the risk of potentially serious complications. 
Sclerotherapy with various sclerosants has been reported with good 
results [6,7] (Fig. 1). However, among the macrocystic (loculation 
volume ≥2 cm
3), microcystic (loculation volume <2 cm
3), and mixed US-guided sclerotherapy for benign cervical cyst
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types, the microcystic and mixed types showed a lower response 
rate for sclerotherapy than the macrocystic type [7,12,14]. For these 
types, surgery should be considered rather than sclerotherapy [15]. 
OK-432 has been the most widely reported sclerosing agent in these 
cases [12,16] and has been reported to be effective in up to 96% of 
patients undergoing sclerotherapy for lymphatic malformation in the 
neck space, with a long-term response rate of 76.3% [6]. Because 
the therapeutic response to OK-432 usually takes about 6 weeks or 
more, and because the number of injections does not correlate with 
the success rate and surgical excision is not considered to be more 
difficult after OK-432 sclerotherapy, the exact timing of conversion 
from sclerotherapy to surgical excision should be chosen carefully [6].
Impellizzeri et al. [8] reported a group of 8 patients who underwent 
computed tomography (CT)-guided ethanol sclerotherapy for 
lymphatic malformation. The cysts showed complete disappearance 
after 1 injection in 7 patients, and there were satisfactory results 
after 2 injections in 1 patient. There were no significant complications 
associated with the injection of 98% sterile ethanol in an amount 
equivalent to 50% of the aspirate fluid volume [8]. 
Puig et al. [17] applied a double-needle procedure to reduce the 
risk of intralesional pressure elevation and alcohol extravasation in 
the surrounding tissues in the fluoroscopy-guided sclerotherapy. 
Results of sclerotherapy using doxycycline, bleomycin, and 
Ethibloc for lymphatic malformation have also been published [12], 
and in a meta-analysis by Adams et al. [18] comparing surgery 
with sclerotherapy, complications were reported more frequently 
with surgery, but which treatment is more effective was not clearly 
established. 
Ranula
A ranula is a pseudocyst or mucocele caused by the leakage of 
mucus from the sublingual or minor salivary gland. The wall is 
formed by granulation tissue, connective tissue, or fibrous tissue, 
and is without epithelium [19,20]. 
Surgical excision of a ranula along with the sublingual gland has 
traditionally been the first choice of therapy. However, incomplete 
excision resulting in eventual recurrence occurs frequently because 
the ranula is easily ruptured during surgery owing to its thin and 
friable wall. In addition, there is risk of injury of surrounding vital 
structures, including the lingual nerve and the submandibular duct 
[19,20]. 
Ranulas are classified into intraoral and plunging types. An 
intraoral ranula is confined to the floor of the mouth and is a slowly 
enlarging painless fluctuant swelling. In contrast, a plunging-
type ranula is a pseudocyst formed by mucus extravasation arising 
from the sublingual gland located below the mylohyoid muscle; 
it presents as a swelling in the upper part of the neck. According 
to Jain et al. [21], all 30 cases of plunging ranula showed either 
solid echogenic material, fluid material, or both, which suggested 
the herniation through the defect of mylohyoid muscle from the 
sublingual space to the submandibular space in their study (Fig. 2).
Because intraoral ranulas have the tendency to rupture after 
sclerotherapy, the overall outcome of sclerotherapy for a plunging-
type ranula is better than that for an intraoral ranula [19]. Rho 
[19] has reported effective treatment of plunging-type ranulas by 
injection of a volume of 1 KE OK-432 in 10 mL of normal saline 
solution equivalent to the amount of aspirated cyst fluid (Fig. 2). 
Complete sclerotherapy encompassing the entire plunging tract 
Fig. 1. A 54-year-old man with a macrocystic lymphatic malformation treated with ethanol.
A. Ultrasonography reveals a large cystic mass in the right supraclavicular area. B. After treatment with ethanol, the cystic mass decreased 
markedly, resulting in a small echogenic lesion (arrows). 
A BJi-hoon Kim
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of the plunging-type ranula seems to be important for effective 
treatment. 
Branchial Cleft Cyst
Although surgery is also a standard treatment for a branchial cleft 
cyst, Kim et al. [22] have highlighted the potential for the success of 
the OK-432 treatment by presenting results for 14 of 23 cases of a 
unilocular branchial cleft cyst that showed complete disappearance 
after injection of OK-432. Furthermore, in a study by Roh et al. [23], 
7 of 12 patients had a complete response to OK-432 injections after 
1-3 treatments performed as those described above (i.e., 1 KE OK-
432 in 10 mL of normal saline at a volume equivalent to the amount 
of aspirated cyst fluid). Fukumoto has also reported successful 
results of ethanol sclerotherapy for the treatment of a branchial cleft 
cyst [24]. It is important to perform CT to exclude the possibility of 
branchiogenic carcinoma or other head and neck malignancy before 
sclerotherapy for branchial cleft cyst. According to Goyal et al. [25], 
a branchial cleft cyst is frequently large in size and has homogenous 
Fig. 3. A 52-year-old woman with a left tonsillar cancer. Computed 
tomography reveals a cystic mass with septation (arrowheads) in 
left level II.
Fig. 2. A 17-year-old girl with a plunging-type ranula treated with 
OK-432.
A. Computed tomography reveals a lobulated cystic mass in the 
left submandibular space (arrows). B. Ultrasonography reveals an 
insinuating septated mass (arrows) that herniates from the sublingual 
space into the left submandibular space through the mylohyoid 
muscle (black arrowheads). The herniating tract (white arrowheads) 
between the sublingual space and the submandibular space is seen 
as an echogenic tubular structure. C. After three treatments with 
OK-432, the lesion disappeared completely. 
C
A BUS-guided sclerotherapy for benign cervical cyst
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features; further, malignant cystic adenopathy showed a frequently 
extracapsular spread and septation (Fig. 3). 
Thyroglossal Duct Cyst
Simple excision methods for thyroglossal duct cysts are associated 
with high recurrence rates of up to 40%-65%. This recurrence 
rate can be reduced to 2.6%-5% by the Sistrunk procedure. The 
extended Sistrunk operation, in which the central core of the soft 
tissue at the anterior neck compartment, from the thyroid gland to 
the tongue base in addition to the hyoid bone and the fibrous tract, 
is dissected and removed, has been advocated to prevent recurrence 
[26,27]. The drawbacks of this surgical procedure include the use 
of general anesthesia, the extent of scarring, and the associated 
surgical morbidity [26,27]. 
Up to one-third of the patients present with a concurrent or 
previous history of infection in the cyst [28]. The presence of 
inflammation at the time of surgery is an important risk factor for 
relapse, and the initial treatment should be the administration of 
antibiotics in the sclerotherapy as well as in the surgery [29]. As a 
possible alternative, Kim et al. [1] have reported complete regression 
of a thyroglossal duct cyst after sclerotherapy with 1 KE OK-432 in 
10 mL of normal saline at a volume equivalent to the cyst aspirate 
in 5 of 11 patients, and although its use is still rare, there have been 
a few reports of successful ethanol sclerotherapy for these cysts. 
Further, as described by Kim et al. [27], in one series of 11 patients, 
there was significant improvement of symptom grade and cosmetic 
grade along with a mean volume reduction of 81.3% in thyroglossal 
duct cysts after ethanol sclerotherapy. In these cases, the treatment 
consisted of injection of a volume of ethanol equivalent to 50%-
80% of the aspirate volume, which followed aspiration of as much 
A B
Fig. 4. A 30-year-old woman with a thyroglossal duct cyst. 
A. Computed tomography reveals a cystic mass (arrow) at the 
anterior and inferior aspects of the hyoid bone. B. Ultrasonography 
reveals a cystic mass. C. After the treatment with ethanol, the lesion 
decreased in size. 
CJi-hoon Kim
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Special care must be taken to avoid ethanol leakage during 
sclerotherapy for these lesions, because most of them are located 
near the recurrent laryngeal nerve or the tracheoesophageal groove. 
To minimize leakage of ethanol outside the parathyroid cyst, Sung et 
al. [31] inserted the needle via the normal thyroid tissue.
Lymphocele
A lymphocele is a benign cyst, usually unilocular, that may occur 
spontaneously or after trauma or surgery [33]. Although resection 
of a lymphocele accompanied by ligation of the involved lymphatic 
duct is the standard surgical method, there have been a few reports 
of sclerotherapy using OK-432 or talc as a treatment of these cysts 
[33-35]. 
Conclusion
Sclerotherapy is currently recommended as a less invasive method 
before surgery for the treatment of a variety of benign non-thyroid 
cystic masses of the neck. Among the available sclerosants, OK-
432 has been well-established as a safe and effective agent that 
has proven useful for the ablation of several different types of cystic 
masses of the neck. However, OK-432 may be difficult to obtain in a 
routine clinical setting. In addition, the recurrence rate of cysts and 
the occurrence of inflammatory reactions after sclerotherapy using 
OK-432 are not negligible. Therefore, although its side effects are 
reported to be slightly greater than those of OK-432, ethanol, which 
is a more potent and more easily accessible sclerosing agent, has 
been currently used in many hospitals in Korea. Nonetheless, further 
investigation of the techniques for the safer use of ethanol should 
fluid as possible [24,26,27] (Fig. 4). In some cases, the authors 
used a suction pump to facilitate the aspiration of the cyst, because 
thyroglossal duct cysts often contain a very sticky fluid [27]. They 
performed needle puncture at the most nondependent portion of the 
lesion to minimize ethanol leakage [27]. It has been acknowledged 
that the efficacy of ethanol sclerotherapy for a thyroglossal duct 
cyst still needs to be validated on a larger scale [27], and as with a 
branchial cleft cyst, sclerotherapy in the case of a thyroglossal duct 
cyst must be carefully preformed only after the exclusion of the 
accompanying thyroid cancer. According to Branstetter et al. [30], CT 
features suggestive of thyroid duct carcinoma include mural nodules 
and calcification. 
Parathyroid Cyst
Parathyroid cysts are classified into functional and nonfunctional 
cysts. Most functional cysts originate from a cystic change 
of parathyroid adenoma and therefore, exhibit a solid cystic 
appearance on ultrasonography. Most nonfunctional cysts appear 
as pure cystic structures on ultrasonography and yield a clear, 
colorless fluid aspirate [31]. In some cases, differentiation of a 
parathyroid cyst from a thyroid cyst is difficult and can be achieved 
by the measurement of the parathyroid hormone in the cystic 
fluid [31,32]. Sung et al. [31] have successfully treated 4 patients 
with a nonfunctioning parathyroid cyst by simple aspiration, and 
in 8 patients who had recurrence of a nonfunctioning parathyroid 
cyst after simple aspiration, the authors successfully treated the 
recurrent cysts by injection of an ethanol volume that was <50% of 
the aspirate volume (Fig. 5). In this series, there were no significant 
complications reported in any of the 12 cases described [31]. 
Fig. 5. A 63-year-old woman with a parathyroid cyst. 
Transverse (A) and sagittal (B) ultrasonography reveals a lobulated pure cystic mass (arrows) in the inferior aspect of the left thyroid gland. 
After treatment with ethanol, the lesion disappeared completely.
A BUS-guided sclerotherapy for benign cervical cyst
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be pursued, and when the other sclerosing agents are used, the 
individual characteristics and complications associated with each 
should be reviewed before sclerotherapy. 
ORCID: Ji-hoon Kim: http://orcid.org/0000-0002-6349-6950
Conflict of Interest
No potential conflict of interest relevant to this article was reported.
References
  1.  Kim MG, Kim SG, Lee JH, Eun YG, Yeo SG. The therapeutic 
effect of OK-432 (picibanil) sclerotherapy for benign neck cysts. 
Laryngoscope 2008;118:2177-2181.
  2.  Colbert SD, Seager L, Haider F, Evans BT, Anand R, Brennan PA. 
Lymphatic malformations of the head and neck-current concepts in 
management. Br J Oral Maxillofac Surg 2013;51:98-102. 
  3.  Sung MW, Lee DW, Kim DY, Lee SJ, Hwang CH, Park SW, et al. 
Sclerotherapy with picibanil (OK-432) for congenital lymphatic 
malformation in the head and neck. Laryngoscope 2001;111:1430-
1433.
  4.  Roh JL, Kim HS. Primary treatment of pediatric plunging ranula with 
nonsurgical sclerotherapy using OK-432 (Picibanil). Int J Pediatr 
Otorhinolaryngol 2008;72:1405-1410. 
  5.  Rho MH, Kim DW, Kwon JS, Lee SW, Sung YS, Song YK, et al. OK-
432 sclerotherapy of plunging ranula in 21 patients: it can be a 
substitute for surgery. AJNR Am J Neuroradiol 2006;27:1090-1095. 
  6.  Wiegand S, Eivazi B, Zimmermann AP, Sesterhenn AM, Werner JA. 
Sclerotherapy of lymphangiomas of the head and neck. Head Neck 
2011;33:1649-1655.
  7.  Ogita S, Tsuto T, Tokiwa K, Takahashi T. Intracystic injection of OK-
432: a new sclerosing therapy for cystic hygroma in children. Br J 
Surg 1987;74:690-691.
  8.  Impellizzeri P, Romeo C, Borruto FA, Granata F, Scalfari G, De Ponte 
FS, et al. Sclerotherapy for cervical cystic lymphatic malformations 
in children: our experience with computed tomography-guided 
98% sterile ethanol insertion and a review of the literature. J 
Pediatr Surg 2010;45:2473-2478.
  9.  Mason KP, Michna E, Zurakowski D, Koka BV, Burrows PE. Serum 
ethanol levels in children and adults after ethanol embolization or 
sclerotherapy for vascular anomalies. Radiology 2000;217:127-
132.
10.  Gelczer RK, Charboneau JW, Hussain S, Brown DL. Complications 
of percutaneous ethanol ablation. J Ultrasound Med 1998;17:531-
533.
11.  Alomari AI, Karian VE, Lord DJ, Padua HM, Burrows PE. 
Percutaneous sclerotherapy for lymphatic malformations: a 
retrospective analysis of patient-evaluated improvement. J Vasc 
Interv Radiol 2006;17:1639-1648.
12.  Renton JP, Smith RJ. Current treatment paradigms in the 
management of lymphatic malformations. Laryngoscope 
2011;121:56-59.
13.  Kim CH, Rho MH. OK-432 sclerotherapy for benign cystic head and 
neck lesions. J Korean Radiol Soc 2003;49:461-467.
14.  Ogita S, Tsuto T, Nakamura K, Deguchi E, Iwai N. OK-432 therapy in 
64 patients with lymphangioma. J Pediatr Surg 1994;29:784-785.
15.  Gilony D, Schwartz M, Shpitzer T, Feinmesser R, Kornreich L, Raveh 
E. Treatment of lymphatic malformations: a more conservative 
approach. J Pediatr Surg 2012;47:1837-1842. 
16.  Balakrishnan K, Menezes MD, Chen BS, Magit AE, Perkins JA. 
Primary Surgery vs Primary Sclerotherapy for Head and Neck 
Lymphatic Malformations. JAMA Otolaryngol Head Neck Surg 
2014;140:41-45.
17.  Puig S, Aref H, Brunelle F. Double-needle sclerotherapy of 
lymphangiomas and venous angiomas in children: a simple 
technique to prevent complications. AJR Am J Roentgenol 
2003;180:1399-1401. 
18.  Adams MT, Saltzman B, Perkins JA. Head and neck lymphatic 
malformation treatment: a systematic review. Otolaryngol Head 
Neck Surg 2012;147:627-639.
19.  Roh JL. Primary treatment of ranula with intracystic injection of OK-
432. Laryngoscope 2006;116:169-172.
20.  Lee HM, Lim HW, Kang HJ, Chae SW, Hwang SJ, Jung KY, et al. 
Treatment of ranula in pediatric patients with intralesional injection 
of OK-432. Laryngoscope 2006;116:966-969.
21.  Jain P, Jain R, Morton RP, Ahmad Z. Plunging ranulas: high-
resolution ultrasound for diagnosis and surgical management. Eur 
Radiol 2010;20:1442-1449. 
22.  Kim MG, Lee NH, Ban JH, Lee KC, Jin SM, Lee SH. Sclerotherapy of 
branchial cleft cysts using OK-432. Otolaryngol Head Neck Surg 
2009;141:329-334.
23.  Roh JL, Sung MW, Hyun Kim K, Il Park C. Treatment of branchial 
cleft cyst with intracystic injection of OK-432. Acta Otolaryngol 
2006;126:510-514.
24.  Fukumoto K, Kojima T, Tomonari H, Kontani K, Murai S, Tsujimoto 
F. Ethanol injection sclerotherapy for Baker's cyst, thyroglossal duct 
cyst, and branchial cleft cyst. Ann Plast Surg 1994;33:615-619. 
25.  Goyal N, Zacharia TT, Goldenberg D. Differentiation of branchial 
cleft cysts and malignant cystic adenopathy of pharyngeal origin. 
AJR Am J Roentgenol 2012;199:W216-W221.
26.  Chow TL, Choi CY, Hui JY. Thyroglossal duct cysts in adults treated 
by ethanol sclerotherapy: a pilot study of a nonsurgical technique. 
Laryngoscope 2012;122:1262-1264.
27.  Kim SM, Baek JH, Kim YS, Sung JY, Lim HK, Choi H, et al. Efficacy 
and safety of ethanol ablation for thyroglossal duct cysts. AJNR Am 
J Neuroradiol 2011;32:306-309.
28.  Foley DS, Fallat ME. Thyroglossal duct and other congenital midline 
cervical anomalies. Semin Pediatr Surg 2006;15:70-75. Ji-hoon Kim
90   Ultrasonography 33(2), April 2014  e-ultrasonography.org
29.  Kaselas Ch, Tsikopoulos G, Chortis Ch, Kaselas B. Thyroglossal 
duct cyst's inflammation. When do we operate? Pediatr Surg Int 
2005;21:991-993.
30.  Branstetter BF, Weissman JL, Kennedy TL, Whitaker M. The CT 
appearance of thyroglossal duct carcinoma. AJNR Am J Neuroradiol 
2000;21:1547-1550.
31.  Sung JY, Baek JH, Kim KS, Lee D, Ha EJ, Lee JH. Symptomatic 
nonfunctioning parathyroid cysts: role of simple aspiration and 
ethanol ablation. Eur J Radiol 2013;82:316-320.
32.  Wakabayashi K, Takahashi T, Tejima S. Parathyroid cyst. Nihon 
Rinsho 1995;53:1004-1007. 
33.  Hamilton BE, Nesbit GM, Gross N, Andersen P, Sauer D, Harnsberger 
HR. Characteristic imaging findings in lymphoceles of the head and 
neck. AJR Am J Roentgenol 2011;197:1431-1435.
34.  Roh JL, Park CI. OK-432 sclerotherapy of cervical chylous 
lymphocele after neck dissection. Laryngoscope 2008;118:999-
1002.
35.  Qureishi A, Silva P, Lamyman A, Cox G. Cervical lymphocoele: a 
simple solution for a complicated problem. Ann R Coll Surg Engl 
2012;94:e79-e80. 